reactogenicity – Page 15 – Communicable Diseases Research

Personalized health and the coronavirus vaccines—Do individual genetics matter?

Review

Published on 2021-07-262023-07-02
Journal: Bioessays [Category] SARS,

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

건강한 성인의 코로나바이러스 질병 2019에 대한 재조합 융합 단백질 백신(V-01)의 면역원성과 안전성: 무작위 배정, 이중 맹검, 위약 대조, 2상 시험

Clinical Trial

Published on 2021-07-222022-09-12
Journal: Chinese medical journal [Category] SARS, 임상, 진단,

[키워드] acute respiratory syndrome Adults adverse event AEs age anti-RBD Antigen appear China clinical trial clinical trials confidence interval Control convalescent serum coronavirus coronavirus disease COVID-19 COVID-19 patient demonstrated distribution dose regimen dosing regimens double-blind Efficacy elevated Endpoint Frequency fusion protein geometric mean titer group Guangdong healthy IFN-PADRE-RBD-Fc dimer immune response immune responses immunization immunogenic immunogenicity Immunoglobulin imperative indicated initiated injection intramuscularly less mild in severity neutralizing antibody Older pandemic participant peaked percentage Phase I Placebo placebo-controlled Preliminary data preliminary finding prevention primary immunogenicity Randomized RBD reactogenicity receive Receptor binding domain recombinant COVID-19 vaccine recombinant fusion protein recruited regimen remained robust Safe safety profile significantly specific binding antibody Support symptomatic Trial two-dose regimen V-01 Vaccine vaccine candidate Vaccines
[DOI] 10.1097/CM9.0000000000001702 PMC 바로가기 [Article Type] Clinical Trial

COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience

Article

Published on 2021-07-162022-10-31
Journal: Cancers [Category] COVID-19,

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

청소년에서 BNT162b2 Covid-19 백신의 안전성, 면역원성 및 효능

Randomized Controlled Trial

Published on 2021-07-152022-09-12
Journal: The New England Journal of Medicine [Category] 임상, 진단,

[키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome Adolescent Adults adverse events age assigned BNT162b2 BNT162b2 vaccine Cohort contribute coronavirus coronavirus disease criterion dose effective effective vaccine Efficacy Emergency use Evidence facilitate fatigue geometric mean ratio greater groups headache immune response Immunity immunogenicity indicated Injection-site pain Injections Mild-to-moderate Neutralizing titer observer-blinded occurred of BNT162b2 participant Placebo placebo recipients placebo-controlled produced PROTECT Randomly reactogenicity receive recipient recipients Safety safety profile SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event severe adverse events Side-effect Trial two-sided Vaccine were assessed
[DOI] 10.1056/NEJMoa2107456 PMC 바로가기 [Article Type] Randomized Controlled Trial

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England

Rapid Communication

Published on 2021-07-152022-10-31
Journal: Eurosurveillance [Category] COVID-19, SARS,

[키워드] BNT162b2 ChAdOx1/nCoV-19 Comirnaty COVID-19 COVID-19 vaccination COVID-19 vaccine dose England Heterologous heterologous schedule homologous mRNA Prime-boost reaction reactogenicity receiving Vaccine Vaxevria women
[DOI] 10.2807/1560-7917.ES.2021.26.28.2100634 PMC 바로가기 [Article Type] Rapid Communication

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Clinical Trial

Published on 2021-07-102022-10-05
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 95% CI Abstract Administered adverse events age antibody assigned AstraZeneca baseline BNT162b2 booster Cellular immune response ChAdOx1-S control group Controlled trial COVID-19 dose Efficacy enrolled EudraCT FIVE French geometric mean titre Germany headache Heterologous Human IgG immune response immunoassay immunogenicity immunological individual injection site pain interferon-γ Intervention intervention group Intramuscular injection Local Mainz material men Mild moderate multicentre myalgia observation of BNT162b2 Open-label outcome Oxford participant phase 2 trial primary analysis Primary outcome pseudovirus neutralisation assay randomised Randomly RBD RBD protein reaction reactogenicity reactogenicity profile receive Receptor binding domain Registered reported robust safety analysis SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Event single dose Spain Spanish systemic adverse events translation Trimeric spike protein university hospital vaccination schedule women
[DOI] 10.1016/S0140-6736(21)01420-3 PMC 바로가기 [Article Type] Clinical Trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

비활성화된 SARS-CoV-2 백신, BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 다기관, 2상 시험 및 이중 맹검, 무작위 1상 시험의 3개월 추적 조사의 중간 결과

Clinical Trial

Published on 2021-07-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단,

[키워드] 1:1 95% CI Abstract addition Administered Antigen assigned baseline Bharat block blood draw cell-mediated immune response clinical trial collected defined dose double-blind Efficacy elevated elicited enrolled evaluate first dose Follow-up geometric mean GMT healthy high neutralising antibody Hindi hospital humoral inactivated India intramuscular dose investigators Local material microneutralisation test MNT multicentre neutralisation test neutralising antibody titre nine outcomes participant phase 1 trial Phase 2 study phase 2 trial Phase 3 positive Primary outcome PRNT proportion randomisation randomised Randomly reactogenicity receive Registered remained reported response Safety SARS-CoV-2 SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened second dose second vaccination secondary outcome selected Serious Adverse Event seroconversion rate serology test significant difference significantly higher Sponsor T-cell Response Th1 phenotype the vaccine titre Toll-like receptor translation treatment group Trial Vaccine was done were assessed were excluded wild-type
[DOI] 10.1016/S1473-3099(21)00070-0 PMC 바로가기 [Article Type] Clinical Trial

Vaccination against COVID-19 infection: the need of evidence for diabetic and obese pregnant women

Perspectives

Published on 2021-06-282022-10-28
Journal: Acta Diabetologica [Category] COVID-19, MERS, SARS,

[키워드] affected Breastfeeding COVID COVID-19 COVID-19 infection COVID-19 vaccination develop diabete diabetes Diabetic diabetics disease Efficacy Evidence feasibility fetal Health Organization Healthcare professional high risk Hospitalization Humoral immunity immune transfer Infection intensive care International lactating lactating women lactation morbidity mRNA mRNA vaccination National Neonatal Newborn obese obesity outcome Patient Perspective potential benefit Pregnancy pregnant pregnant women promote Prospective Study reactogenicity Result risk robust SARS-CoV-2 Symptom tested the vaccine Trigger vaccination vaccination against COVID-19 Vaccine with COVID-19 women
[DOI] 10.1007/s00592-021-01764-0 PMC 바로가기 [Article Type] Perspectives

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

HIV 감염에서 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 2/3 상 임상 시험의 단일 암 보체.

Clinical Trial

Published on 2021-06-182022-08-13
Journal: The Lancet. HIV [Category] MERS, SARS, 임상, 진단,

[키워드] ACHE age All participants analysed analyses anti-Spike IgG anti-spike IgG response Anti-spike IgG responses antibody Antiretroviral therapy ART AstraZeneca available data AZD1222 CD4 CD4 cell CD4 count CD4 counts Cell cell-mediated immune response Cell-mediated immune responses cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 chill chills Clinical research clinical trial Coalition Comorbidity determined by dose Eligible participants ELISA ELISPOT enrolled enrolment enzyme enzyme-linked immunospot assay fatigue finding FIVE frequencies Frequency functional funding General population headache HIV HIV clinics HIV-negative HIV-uninfected humoral Humoral response humoral responses IFN-γ IgG response IgG responses immune responses Immunity immunogenic immunogenicity injection injection site Innovation IQR joint joint pain less Live virus Local London magnitude malaise male median median age muscle ache nausea network neutralisation NIHR NIHR Oxford Biomedical Research Centre no correlation no difference occurred Open-label outcome Oxford Pain participant Participants peaked people with HIV persistence phase 2/3 phase 2/3 trial plasma Primary outcome Primary outcomes prime-boost regimen proliferation proliferative protocol reactogenicity Registered reported required response Safe Safety SARS-CoV-2 SARS-CoV-2 spike-specific Serious Adverse Event Serious Adverse Events single-arm South sustained systemic reaction systemic reactions T-cell the vaccine undetectable vaccination Vaccine vaccine immunogenicity Valley Viral Viral load were measured with HIV
[DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Ad26.COV2.S 코비드-19 백신의 1-2a상 시험 중간 결과

Clinical Trial

Published on 2021-05-132022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus administration adverse event age All participants Antibody Response assigned authority candidate vaccine CD4+ T-cell CD8+ T-cell Cohort cohorts collected coronavirus coronavirus disease Coronavirus disease 2019 COV1001 COV2.S Department development dose Factor fatigue Fever full-length geometric mean geometric mean titer GMT headache healthy High dose Human increase in Infection Injection-site pain Interim Johnson & Johnson less low dose milliliter multicenter myalgia Neutralizing-antibody Neutralizing-antibody titers Older pandemic participant phase Placebo placebo-controlled primary end point profile provided Randomly reached reactogenicity receive regimen remained reported research and development respiratory response responses Result robust SARS-CoV-2 SARS-CoV-2 spike protein second dose serotype severe acute respiratory syndrome Coronavirus Spike protein Support systemic systemic adverse events T cells T-cell responses titer titers Trial two-dose regimen type 1 helper Vaccine vaccine candidate vaccine dose Viral viral particle wild-type virus
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial